Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1999 Dec;16(4):261-6.
doi: 10.1007/BF02785872.

Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282

Y Novik  1 , L M Ryan, D G Haller, R Asbury, J P Dutcher, A Schutt
Affiliations
Clinical Trial

Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282

Y Novik et al. Med Oncol. 1999 Dec.

Abstract

The study was a Phase II randomized study to evaluate the efficacy of new agents for the treatment of advanced gastric carcinoma. Patients were randomized to receive single agent chemotherapy with mitoxantrone, etoposide, aclacinomycin-A or spirogermanium. The patients were stratified by prior use of chemotherapy, prior doxorubicin use and ECOG performance status. Patients with a history of cardiac disease or prior doxorubicin exceeding a dose of 400 mg/m2 were restrictively randomized to sopirogermanium or etoposide only. One hundred and fourteen patients were registered for the study. Among 98 evaluable patients there were only two partial responses (both in the etoposide arm), and one complete response in the mitoxantrone arm. The median survival on the study was 3.3 months. One hundred and six patients were analyzable for toxicity. There were four treatment-related deaths and four life-threatening toxicities. Because of low response rates and relatively high toxicities the studied compounds were not deemed worth further investigation for advanced gastric cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Invest New Drugs. 1989 Jul;7(2-3):223-4 - PubMed
    1. Cancer Treat Rep. 1983 May;67(5):509-10 - PubMed
    1. Am J Clin Oncol. 1994 Apr;17(2):166-9 - PubMed
    1. Invest New Drugs. 1990 Feb;8(1):65-70 - PubMed
    1. Semin Oncol. 1996 Jun;23(3):397-406 - PubMed

Publication types

MeSH terms

LinkOut - more resources